BIOSGN — Biosergen AB Share News
0.000.00%
Last trade - 00:00- SEK17.61m
- -SEK5.10m
Brief: Biosergen Q3 EBITDA Loss Narrows To SEK 7.5 Mln
Development, License Deal For BSG005
Brief: Biosergen Announces Outcome Of Exercise Of Warrants Series TO2
Brief: Biosergen CEO, CFO To Subscribe To All Of Their Warrants
Brief: Biosergen Q2 EBITDA Loss At SEK 8.0 Mln
Brief: Biosergen Publishes Reports Qtrly Loss Before Depreciation SEK 5 MLN
Brief: Biosergen Q4 EBITDA Loss Widens To SEK 12.5 Mln
Brief: Biosergen Provides Phase 2 Clinical Development Strategy Update
Brief: Biosergen Q3 Net Loss Widens To SEK 14.5 Mln
Brief: Biosergen To Receive About SEK 42.2 Mln Through Rights Issue
Brief: Biosergen Decides On Rights Issue Of About SEK 60.2 Mln
Brief: Biosergen Q2 Consolidated Net Loss SEK 8 Million
Brief: Biosergen Receives Loan Of SEK 7 Million
Brief: Biosergen Q1 Consolidated Net Loss Narrows To SEK 5 Million
Brief: Biosergen Completes First Cohort Of Bsg005 Phase I Trial
Brief: Biosergen AB Says First Subject Dosed In Phase I Trial Of BSG005
Brief: Biosergen Q4 Consolidated Net Loss At SEK 15.0 Million
Brief: Biosergen Q3 Consolidated Net Loss SEK 6.7 Mln
Brief: Biosergen Q2 Net Loss At SEK 12.6 Million